Liens rapides
Catégories
Fiches d'information
Les fiches d'information fournissent des informations supplémentaires sur l'industrie mondiale des protéines plasmatiques thérapeutiques.
Publications et présentations
Discover the main highlights of our industry in our latest publications.
Ressources pour les patients
Explorez les ressources de PPTA pour les patients intéressés par les thérapies aux protéines plasmatiques.
Rapports des parties prenantes
Apprenez-en plus en accédant à la collection de rapports de l'industrie.
Actualités et communiqués de presse
Restez au courant de l'actualité et des événements de l'Association.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Mar 4, 2026
Donor Safety Comes First: How the Plasma Industry Protects Donors
All
Blog Posts
Mar 4, 2026
Donor Safety Comes First: How the Plasma Industry Protects Donors
All
Blog Posts
Feb 24, 2026
More Moments Together: How Plasma-Derived Therapies Keep My Dad Strong
All
Blog Posts
Feb 24, 2026
More Moments Together: How Plasma-Derived Therapies Keep My Dad Strong
All
Blog Posts
Feb 23, 2026
PPTA Response to GUARD Model
In conclusion, PPTA reiterates its recommendation that CMS exempt PDTs from the GUARD Model. This policy is also consistent with the CMMI statute, which requires that Models to be tested “preserv[e] or enhance[e] the quality of care furnished to individuals [with Medicare].”18 Excluding PDTs from the GUARD Model is fully consistent with this statutory requirement.
All
Advocacy
https://cdn.prod.website-files.com/6916f1777886bb3b9377a752/69b07ddb20ebd5d78daf5cf0_PPTA%20Response%20to%20GUARD%20Model.pdf
Feb 23, 2026
PPTA Response to GUARD Model
In conclusion, PPTA reiterates its recommendation that CMS exempt PDTs from the GUARD Model. This policy is also consistent with the CMMI statute, which requires that Models to be tested “preserv[e] or enhance[e] the quality of care furnished to individuals [with Medicare].”18 Excluding PDTs from the GUARD Model is fully consistent with this statutory requirement.
All
Advocacy
https://cdn.prod.website-files.com/6916f1777886bb3b9377a752/69b07ddb20ebd5d78daf5cf0_PPTA%20Response%20to%20GUARD%20Model.pdf
Feb 23, 2026
PPTA Response to GLOBE Model
PPTA urges CMS to exempt PDTs from the GLOBE Model. This policy is also consistent with the CMMI statute, which requires that Models to be tested “preserv[e] or enhance[e] the quality of care furnished to individuals [with Medicare].”18 Excluding PDTs from the GLOBE Model is fully consistent with this statutory requirement.
All
Advocacy
https://cdn.prod.website-files.com/6916f1777886bb3b9377a752/69b07ddb6579d5986b8beb40_PPTA%20Response%20to%20GLOBE%20Model%20-%20Final.pdf
Feb 23, 2026
PPTA Response to GLOBE Model
PPTA urges CMS to exempt PDTs from the GLOBE Model. This policy is also consistent with the CMMI statute, which requires that Models to be tested “preserv[e] or enhance[e] the quality of care furnished to individuals [with Medicare].”18 Excluding PDTs from the GLOBE Model is fully consistent with this statutory requirement.
All
Advocacy
https://cdn.prod.website-files.com/6916f1777886bb3b9377a752/69b07ddb6579d5986b8beb40_PPTA%20Response%20to%20GLOBE%20Model%20-%20Final.pdf
Aucun résultat n'a été trouvé